Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance
- PMID: 11514524
- PMCID: PMC95423
- DOI: 10.1128/JB.183.18.5385-5394.2001
Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance
Abstract
Biofilms are a protected niche for microorganisms, where they are safe from antibiotic treatment and can create a source of persistent infection. Using two clinically relevant Candida albicans biofilm models formed on bioprosthetic materials, we demonstrated that biofilm formation proceeds through three distinct developmental phases. These growth phases transform adherent blastospores to well-defined cellular communities encased in a polysaccharide matrix. Fluorescence and confocal scanning laser microscopy revealed that C. albicans biofilms have a highly heterogeneous architecture composed of cellular and noncellular elements. In both models, antifungal resistance of biofilm-grown cells increased in conjunction with biofilm formation. The expression of agglutinin-like (ALS) genes, which encode a family of proteins implicated in adhesion to host surfaces, was differentially regulated between planktonic and biofilm-grown cells. The ability of C. albicans to form biofilms contrasts sharply with that of Saccharomyces cerevisiae, which adhered to bioprosthetic surfaces but failed to form a mature biofilm. The studies described here form the basis for investigations into the molecular mechanisms of Candida biofilm biology and antifungal resistance and provide the means to design novel therapies for biofilm-based infections.
Figures







Similar articles
-
Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines.Infect Immun. 2007 May;75(5):2612-20. doi: 10.1128/IAI.01841-06. Epub 2007 Mar 5. Infect Immun. 2007. PMID: 17339351 Free PMC article.
-
Evaluation of biofilm formation and antimicrobial susceptibility (drug resistance) of Candida albicans isolates.Braz J Microbiol. 2025 Mar;56(1):353-364. doi: 10.1007/s42770-024-01558-w. Epub 2024 Nov 6. Braz J Microbiol. 2025. PMID: 39500825
-
Mechanism of recombinant 1,3-β-glucanase as antibiofilm to prevent antimicrobial resistance in antifungal therapy for vulvovaginitis candidiasis.Open Vet J. 2025 May;15(5):2182-2192. doi: 10.5455/OVJ.2025.v15.i5.36. Epub 2025 May 31. Open Vet J. 2025. PMID: 40557080 Free PMC article.
-
Lipopeptide: Exploration for enhanced anticandidal therapeutic spectrum.Microb Pathog. 2025 Oct;207:107888. doi: 10.1016/j.micpath.2025.107888. Epub 2025 Jul 9. Microb Pathog. 2025. PMID: 40645352 Review.
-
Candida albicans: Insights into the Biology and Experimental Innovations of a Commonly Isolated Human Fungal Pathogen.ACS Infect Dis. 2025 Jul 11;11(7):1780-1815. doi: 10.1021/acsinfecdis.5c00079. Epub 2025 Jun 13. ACS Infect Dis. 2025. PMID: 40512087 Review.
Cited by
-
The effect of biomaterials and antifungals on biofilm formation by Candida species: a review.Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2513-27. doi: 10.1007/s10096-012-1634-6. Epub 2012 May 12. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22581304 Review.
-
Voriconazole is cytotoxic at locally delivered concentrations: a pilot study.Clin Orthop Relat Res. 2013 Oct;471(10):3165-70. doi: 10.1007/s11999-013-2860-7. Clin Orthop Relat Res. 2013. PMID: 23436188 Free PMC article.
-
Conserved and divergent roles of Bcr1 and CFEM proteins in Candida parapsilosis and Candida albicans.PLoS One. 2011;6(12):e28151. doi: 10.1371/journal.pone.0028151. Epub 2011 Dec 1. PLoS One. 2011. PMID: 22145027 Free PMC article.
-
Effect of water-aging on the antimicrobial activities of an ORMOSIL-containing orthodontic acrylic resin.Acta Biomater. 2013 Jun;9(6):6964-73. doi: 10.1016/j.actbio.2013.02.031. Epub 2013 Feb 26. Acta Biomater. 2013. PMID: 23485857 Free PMC article.
-
Gold nanoparticles enhance methylene blue-induced photodynamic therapy: a novel therapeutic approach to inhibit Candida albicans biofilm.Int J Nanomedicine. 2012;7:3245-57. doi: 10.2147/IJN.S31219. Epub 2012 Jun 29. Int J Nanomedicine. 2012. PMID: 22802686 Free PMC article.
References
-
- Albani J R, Plancke Y D. Interaction between calcofluor white and carbohydrates of alpha 1-acid glycoprotein. Carbohydr Res. 1999;318:194–200. - PubMed
-
- Anaissie E J, Rex J H, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998;104:238–245. - PubMed
-
- Austin J W, Bergeron G. Development of bacterial biofilms in dairy processing lines. J Dairy Res. 1995;62:509–519. - PubMed
-
- Bagge N, Ciofu O, Skovgaard L T, Hoiby N. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal β-lactamase. APMIS. 2000;108:589–600. - PubMed
-
- Baillie G S, Douglas L J. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol. 1999;310:644–656. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous